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MyosinBackground: Dilated cardiomyopathy (DCM) is characterized by idiopathic dilatation and systolic contractile
dysfunction of the ventricle(s) leading to an impaired systolic function. The origin of DCM is heterogeneous,
but genetic transmission of the disease accounts for up to 50% of the cases. Mutations in alpha-tropomyosin
(TPM1), a thin ﬁlament protein involved in structural and regulatory roles in muscle cells, are associated with
hypertrophic cardiomyopathy (HCM) and very rarely with DCM. Methods and results: Here we present a
large four-generation family in which DCM is inherited as an autosomal dominant trait. Six family members
have a cardiomyopathy with the age of diagnosis ranging from 5 months to 52 years. The youngest affected
was diagnosed with dilated and non-compaction cardiomyopathy (NCCM) and died at the age of ﬁve. Three
additional children died young of suspected heart problems. We mapped the phenotype to chromosome 15
and subsequently identiﬁed a missense mutation in TPM1, resulting in a p.D84N amino acid substitution. In
addition we sequenced 23 HCM/DCM genes using next generation sequencing. The TPM1 p.D84N was the
only mutation identiﬁed. The mutation co-segregates with all clinically affected family members and signif-
icantly weakens the binding of tropomyosin to actin by 25%. Conclusions: We show that a mutation in TPM1
is associated with DCM and a lethal, early onset form of NCCM, probably as a result of diminished actin bind-
ing caused by weakened charge–charge interactions. Consequently, the screening of TPM1 in patients and
families with DCM and/or (severe, early onset forms of) NCCM is warranted. This article is part of a Special
Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cardiomyopathies are a heterogeneous group of diseases of the
myocardium associated with mechanical and/or electrical dysfunc-
tion of the heart. They occur in isolated forms or as part of generalized
systemic disorders and can lead to cardiovascular death or progres-
sive heart failure-related disabilities. Primary cardiomyopathies
were recently re-classiﬁed into three distinct forms: one with genetic
etiology (e.g. hypertrophic cardiomyopathy (HCM)), one with a
mixed genetic/non genetic etiology (e.g. dilated cardiomyopathy
(DCM), restrictive cardiomyopathy), and one with an acquiredocyte Biology: Cardiac Pathways
ter, Department of Anatomy &
gdreef 15, 1105 AZ, Amsterdam,
6177.
).
rights reserved.etiology (e.g. myocarditis) [1]. DCM and HCM are the most common
forms, with DCM (including mixed/non-genetic etiology) alone ac-
counting for 60% of the cardiomyopathies. Moreover, it is a common
cause of heart failure and, importantly, represents the most frequent
reason for a heart transplantation [1–3]. Idiopathic dilated cardiomy-
opathy is likely to be genetic and is characterized by dilatation and
systolic contractile dysfunction of the left and/or both ventricles and
consequently an impaired systolic function [1], in the absence of sec-
ondary causes for the observed myocardial abnormality. Idiopathic
DCM has an estimated prevalence of about 1:2500 [4,5].
The origin of DCM is heterogeneous, but genetic transmission of
the disease can account for up to 50% in diverse populations [4–6],
with multiple modes of inheritance including autosomal dominant
(~60%), autosomal recessive (~16%), X-linked (~10%) and mitochon-
drial (~8%) [7]. So far DCM has been linked to a diverse group of more
than 30 loci and genes [1,3,8,9] encoding cytoskeletal and costameric
proteins as well as cardiac contractile proteins. Tropomyosin is one of
the ﬁve proteins in the thin ﬁlaments of sarcomeres where it plays
834 J.B.A. van de Meerakker et al. / Biochimica et Biophysica Acta 1833 (2013) 833–839fundamental structural, developmental, and regulatory roles in mus-
cle cells by interacting with actin [10]. Human cardiac muscle and
fast twitch skeletal muscle exclusively contain alpha-tropomyosin
(TPM1) [10,11]. Thus far, only two DCM associated mutations in
TPM1 have been reported in nuclear families [12], in contrast to
HCM for which many TPM1 mutations have been found [13].
Here we present a large four-generation family in which DCM is
inherited as an autosomal dominant trait. Candidate gene linkage
demonstrated linkage to chromosome 15 on which we subsequently
identiﬁed the co-segregating p.D84N TPM1 mutation, which has not
been described before and is absent from over 1100 control chromo-
somes. The mutation shows signiﬁcantly weakened binding of tropo-
myosin to actin, which is corroborated by existing atomic and protein
models.
2. Methods
2.1. Clinical details
Written informed consent was obtained from all patients or their
legal representatives. Family members were evaluated using clinical
history, physical examination, echocardiography and ECG. DCM was
diagnosed according to previously described criteria [14], in short,
the presence of a dilated and poorly functioning left ventricle (ejec-
tion fraction b40%) in the absence of abnormal loading conditions
(hypertension, valve disease) or ischemic heart disease.
2.2. Linkage analysis, mutation screen and conﬁrmation
Genomic DNA (gDNA) of family members was extracted from pe-
ripheral blood according to standard procedures. Linkage analysis
was performed using the ABI linkage set v2.5 on an ABI 3700 Genetic
Analyzer (Applied Biosystems) [15]. Phenotype and genotype data
and pedigree information were combined for multipoint linkage anal-
ysis with the use of the easyLinkage v5.02 software package [16] run-
ning the Merlin program v1.0.1 [17] with the assumption of an
autosomal dominant pattern of inheritance, a disease-allele frequen-
cy of 0.0001, and penetrance of 0.9 for affected individuals. Gene fre-
quency was assumed to be equal between males and females.
Lamin A/C (LMNA) gDNA was PCR ampliﬁed using LMNA speciﬁc
primers (available on request), located in ﬂanking intronic sequences
and analyzed by direct sequencing, using the BigdyeTerminator v3.1
Kit on an ABI 3700. PCR ampliﬁcation of the MYH7, TPM1 and ACTC
genes was performed using primers located in ﬂanking intronic se-
quences (available on request). Subsequently, MYH7 and ACTC PCR
products were analyzed by direct sequencing, as described above.
For TPM1, PCR products were pre-screened using DHPLC according
to standard protocols [18]. Certiﬁed genotypic normal controls were
included in each run so that aberrant proﬁles could be differentiated
from wildtype by visual inspection, aberrant proﬁles were subse-
quently sequenced. Exon 3 of TPM1 was additionally screened in
the whole family by PCR and bi-directional sequence analysis.
2.3. Next generation sequencing
About 5 μg of DNA, isolated from peripheral blood leucocytes using
an automated DNA isolator (Gentra), was fragmented according to the
manufacturer's instructions (Covaris). DNA quality was assessed using
a Bioanalyzer (Agilent). The sample was barcoded using standard
Roche protocols. Libraries were ampliﬁed by linker-mediated PCR.
This sample was part of a mixture of 10 samples that were mixed
equimolarly (3 μg in total) and loaded onto the capture-array according
to the manufacturer's instructions (Nimblegen). To increase target en-
richment, samples were hybridized a second time on the same array.
The enriched librarywas diluted, annealed to capture beads, and clonal-
ly ampliﬁed by emulsion PCR. After emulsion PCR, beads with clonalamplicons were enriched and deposited on a picotiter plate and se-
quenced on the GS FLX Titanium (Roche). The array was custom
designed in such away that all coding exonswere targeted, including
100 bp ﬂanking intronic sequences of 23 candidate genes. In total
the array contained 292 exons, targeting 117.5 kb. The following 23
genes were sequenced: 1. ACTC1 (NM_005159.4); 2. CSRP3 (NM_
003476.3); 3. DES (NM_001927.3); 4. GLA (NM_000169.2); 5.
LAMP2 (NM_002294.2, NM_013995.2, NM_001122606.1); 6. LDB3
(NM_007078.2, NM_001080116.1); 7. LMNA (NM_170707.2,
ENST00000368294, ENST00000368297); 8. MYBPC3 (NM_000256.3);
9. MYH7 (NM_000257.2); 10. MYL2 (NM_000432.3); 11. MYL3 (NM_
000258.2); 12. PLN (NM_002667.3); 13. PRKAG2 (NM_016203.3);14.
SCN5A (NM_198056.2); 15. SGCD (NM_172244.2, NM_000337.4); 16.
STA (NM_000117.2); 17. TAZ (NM_000116.3); 18. TCAP (NM_003673.
2); 19. TNNC1 (NM_003280.1); 20. TNNI3 (NM_000363.4); 21. TNNT2
(NM_000364.2; NM_001001430.1); 22. TPM1 (NM_000366.5, NM_
001018005.1, NM_001018020.1); 23. VCL (NM_014000.2). The average
coveragewas 100±23 reads. All variants of interest were conﬁrmed by
Sanger sequencing.
2.4. Plasmid constructs
Bacterial expression constructs were generated for human TPM1_
WT and TPM1_D84N. A GST-TPM1_WT fusion was created by ligating
theNcoI-SmaI fragment frompOTB7 (Image ID 2962925), encompassing
the entire human TPM1 ORF, into the pGEX2T- (Pharmacia) derived
plasmid pRP265nb [19]. Subsequently the missense mutation D84N
was introduced into this wildtype human TPM1 clone by PCR-based
site-directed mutagenesis (QuickChange II Site-Directed Mutagenesis
Kit, Stratagene) and veriﬁed by sequencing.
2.5. GST-TPM1 afﬁnity puriﬁcation
Escherichia coli BL21 cells transformed with GST-TPM1 bacterial ex-
pression constructswere grown at 37 °C to anOD600 of 0.5 in 100 ml of
LB medium supplemented with 1% glucose. Cells were then induced
with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG, Gibco-BRL)
and transferred to 30 °C for further incubation to minimize proteolysis
and inclusion body formation. After 1–2 h growth, cells were harvested
by centrifugation for 10 min at 10,000 g and then resuspended in 3 ml
of ice-cold resuspension buffer (20 mM Tris pH 7.5, 100 mM NaCl,
2 mM EDTA, 1 mg/ml DNAse and 1 mg/l RNAse). Cell suspensions
were subsequently lysed till a clear lysate was obtained by sonication
(Sonics Vibracell sonicator VC-70, 6× 20–30 s amplitude 80 at 4 °C)
and then centrifuged to pellet cell debris. The cleared lysate containing
the GST fusions was mixed with equal amounts of binding buffer
(20 mMTris pH 7.3, 150 mMNaCl, 0.5% NP-40, 1 mMPMFS and an ap-
propriate amount of protease inhibitor) before passing it over a Gluta-
thione Sepharose resin (Amersham Biosciences) column equilibrated
in binding buffer. The columnwas then washed with 5 ml of PBS buffer
supplemented with 0.05% Triton X-100 before being eluted in fractions
of 100 μl of elution buffer (50 mM Tris pH 8.0, 20 mM L-Glutathione
(Sigma)). Elute fractions were collected, subjected to SDS-PAGE and
PageBlue staining (Fermentas) of the gel.
2.6. Actin-TPM1 co-sedimentation assay and analysis
Rabbit muscle actin was used (Sigma, A2522, 43 kDa). For the assay,
the actin (1 mg/ml) was diluted to 0.4 mg/ml in a buffer containing
5 mM Tris pH 8; 0.2 mM CaCl2; 0.2 mM ATP and 0.5 mM DTT,
centrifuged at 20,000 g for 10 min at 4 °C. The supernatant, which is
monomeric actin was kept on ice for 1 h before polymerization. Actin
polymerization was induced by the addition of 1/10th volume of poly-
merization buffer (500 mM KCl; 20 mM MgCl2 and 1 mM ATP). The
polymerization occurred at room temperature for 1 h. A molar ratio of
actin to puriﬁed GST-TPM1 of 4:1 was used in the binding assay, ﬁnal
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F-actin were incubated in reaction buffer (10 mM Tris pH 7; 2 mM
MgCl2; 1 mM ATP; 0.2 mM DTT and 1 mM EGTA) for 1 h at RT. Tropo-
myosin from porcine muscle (Sigma, T2400, 35 kDa) served as a posi-
tive control. Following incubation, the samples were spun at 130,000–
140,000 g for 30 min at 4 °C using a Beckman airfuge. The rotor was
carefully removed so as not to disturb the pellets. The supernatants
were carefully removed and 5× Laemmli SDS-PAGE sample buffer
was added. The remaining pelletswere dissolved in 1× appropriate vol-
ume and incubated overnight at−20 °C. The relative amounts of pro-
tein in the pellets and supernatants were analyzed following their
separation on a SDS-PAGE gel and PageBlue (Fermentas) staining of
the gel. Subsequently the staining intensity of the actin bands of both
wildtype and mutant proteins in the pellet phase were measured
using Aida 3.44. The experiment was repeated 5 times. Results are
expressed as means±SD. To remove variations from experiments at-
tributable to differences in protein batches and day-to-day handling, a
factor correction was applied [20]. The corrected data set was used for
statistical analysis. Comparisons between wildtype and mutant were
performed using Student's t tests. Pb0.05 was considered statistically
signiﬁcant.2.7. Surface and ribbon model
To create the surface and ribbon model, Deepview version 3.7 was
used. Positive charged side groups are colored blue, negative ones
red. The structural representations are based on the coordinate ﬁles
from the atomic model described by Pirani et al [21].Fig. 1. Pedigree of family with DCM and NCCM, including linkage with microsatellite marke
notype, dotted lines indicate the boundaries of linkage. Carriers of the p.D84N TPM1 mutati
ﬁned DCM, gray ﬁlled symbols mark individuals with suspected DCM phenotype, ·marks o
indicates clinical status obtained from relative of patient, but not investigated by clinic
vidual, the proband is indicated with an arrow. For further clinical details see Table 1.3. Results
3.1. Clinical phenotype
The proband, IV-2, (Fig. 1) was admitted to the hospital at the age of
5 months because of progressive coughing, feeding difﬁculties and
growth retardation. Echocardiography demonstrated an enlarged heart
with severely reduced function. Subsequent investigations, by heart cath-
eterization and amuscle biopsy, didnot showother abnormalities and the
girlwas diagnosed as having an idiopathic dilated cardiomyopathy. At the
age of 2 years the probandhad often been readmitted to the hospitalwith
pneumonia. She had developed atelectasis of part of the left lung, an in-
sufﬁciency of the mitral valve and she was on anticoagulants because of
a cardiac thrombus. Echocardiography later revealed also signs of
non-compaction cardiomyopathy (NCCM). At the age of 4 years and
11 months the proband was admitted to the Intensive Care Unit with
heart failure after surgery of an inguinal hernia. The proband died at
home during her sleep at the age of 5 years and 7 months. Examination
of the family history revealed a theme of heart problems in the family of
the proband's father. The proband's father, III-8, was at the time of the di-
agnosis of his daughter 29 years old andasymptomatic. Subsequent echo-
cardiographic evaluation revealed mild dilatation of the left ventricle and
a slightly decreased ejection fraction. His heart function has remained sta-
ble over the past decade. In addition, echocardiography of the sister of the
proband's father, III-7, revealed a dilatation of the left ventricle, which has
also remained stable over the last decade. The paternal grandfather, II-6,
did not show any abnormalities on echocardiography, but the proband's
paternal grandmother, II-7, had dyspnea on exertion, palpitations and
dizziness at the time of diagnosis of the proband. She was alsors surrounding TPM1 and the resultant 5-3-4-1 haplotype co-segregating with the phe-
on are noted with +, wildtype−. Solid symbols indicate individuals with clinically de-
bligate carrier, and open symbols indicate individuals without DCM phenotype. pr
ian, slashes denoted deceased individuals, age at death is noted at top left of indi-
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husbands. Of the four children of her ﬁrst marriage, one child, II-1, one
of twin siblings, was stillborn. The twin brother, II-2, had a myocardial
infarction at the age of 66 years, though has not been diagnosed with
cardiomyopathy. He had six children, two of whom, III-2 and III-4, died
prior to the age of 6 months of a suspected cardiomyopathy. One son,
III-5, died suddenly at the age of 41, pathological examination revealed
multiple lung emboli and he was shown to have a factor-V Leiden muta-
tion. His heart displayed hypertrophy and was dilated. The youngest
daughter of II-2, III-6, although examined on several occasions, does not
show any cardiological abnormalities. The two sisters of II-2, II-4 and
II-5, have also been diagnosed with DCM. II-4 was diagnosed with DCM
at the age of 51 years, she received an implantable deﬁbrillator (ICD).
Her sister, II-5, showed the presence of DCM when examined upon ad-
mission for heart failure at the age of 52 years. After a syncope and a car-
diac arrest several years later, she also received an ICD. In subsequent
years she had one appropriate ICD discharge and progressive heart failure
developed. She died at the age of 68 yearswaiting for a heart transplanta-
tion. The third marriage of I-2 to I-4 bore four children. One of them, II-8,
died at the age of 6 years from an undeﬁned heart problem, the other
three children have no history of heart problems. The great grandmother
herself, I-2, died at the age of 75, with heart complaints. The results of
phenotypic evaluation are shown in Fig. 1 and Table 1.
3.2. Linkage analysis and mutation screen
Initially, the Lamin A/C gene (LMNA), associated with DCM [22], was
screened, and nomutationswere identiﬁed. Subsequently, we performed
linkage analysis using a list of 22 candidate genes (known tobe associated
with DCM, these genes were also included in the next generation se-
quencing performed in the proband, see below) among all affected and
obligate gene carriers except for IV-2 of whom a limited amount of DNATable 1
Clinical characteristics.
Pedigree Age at
diagnosis
(yrs)
Echocardiography Electrocardiography
LVEDD
(mm)
LVESD
(mm)
FS (%)
IV-2 0.4 57 Dilated 18 Sinustachycardia, high voltages, abnor
repolarization
III-8 29 54 42 22.22 Sinusbradycardia (58 BPM), PQ 184 m
normal repolarization
II-6 – Normal Normal Normal Normal: sinusrhythm, normal PQ and
normal repolarization
II-7 48 53 43 18.87 Normal: sinusrhythm, PQ 160 ms, QRS
mal axis, normal repolarization
III-7 34 54 38 29.63 Normal: PQ 130 ms, QRS 84 ms, norm
repolarization
II-2 – – – – Sinusrhythm, normal PQ time, incomp
QRS 100 ms, repolarization abnormalit
III-2 – – – – –
III-4 – – – – –
III-5 41 – – – –
III-6 – Normal Normal Normal Normal: PQ 178 ms, QRS 76 ms, norm
repolarization
II-4 51 69 62 10 –
II-5 52 Dilated Dilated – Partly pacemaker rhythm, partly LBBB
ular extrasystoles
II-8 – – – – –
I-2 – – – – –
IV-1 – 48 – 42 Normal: PQ 136, QRS 72, normal repol
II-9 – – – – –
II-10 – – – – –
II-11 – – – – –
NCCM = non-compaction cardiomyopathy, SD = sudden death, DCM = dilated cardiomyo
non-sustained ventricular tachycardia, MI = myocardial infarction, ICD = implantable cardwas available. This analysis revealed 2 loci co-segregating with DCM, on
chromosomes 14 and 15 (Fig. 1). Maximal multi-point LOD-scores for
chromosome 14 and 15 were 1.08 and 1.15 respectively, with the loci
being ﬂanked by D14S283/D14S65 and D15S978/D15S127 (Fig. 1).
These loci contain three genes known to be causative for DCM, namely
MYH7, TPM1 and ACTC [8,12,23]. Therefore, mutation analysis was
performed on each of these genes. No mutations in MYH7 or ACTC
were detected, but in exon 3 of TPM1 (NM_001018005) a heterozygous
single-nucleotide variant (c.250G→A, Fig. 2A) was observed in the pro-
band. This nucleotide changewould result, in all TPM1 isoforms, in the re-
placement of a negatively charged aspartic acid for a polar asparagine, at
the highly conserved amino acid position 84, p.D84N (Fig. 2B). This vari-
ant has never been described before in cardiomyopathy patients, it was
not present in 1100 control chromosomes or in over 6500 exomes [24].
In parallel, we performed mutational analysis of exon 3 of TPM1 in all
family members, and found that p.D84N co-segregated with all family
members diagnosedwith a cardiomyopathy. Two familymembers carry-
ing the mutation did not have any signs of DCM, II-2 and III-6, the ﬁrst
being an obligate carrier. If this nucleotide change is included in the link-
age, the LOD score for the chromosome15 locus becomes 1.73. To rule out
additional mutations, we performed next generation sequencing in the
proband on 23 genes known to cause either HCM or DCM. We did not
ﬁnd additional pathogenic mutations besides TPM1 p.D84N.
3.3. Binding of the mutant D84N TPM1 to actin is signiﬁcantly diminished
To investigate the effects of the TPM1mutation on actin binding, we
produced both wildtype and D84N TPM1 protein through afﬁnity puri-
ﬁcation (data not shown). We assayed the binding activity of wildtype
andmutant TPM1 to F-actin using co-sedimentation. Any TPM1 protein
bound to actin should be present in the pellet phase. After centrifugation
the pellet and supernatant phasewere loaded separately on a SDS-PAGECardiac
phenotype
TPM1
genotype
Clinical history
mal DCM, with
signs of NCCM
p.D84N SD at home during sleep at age 5
s, QRS 86 ms, DCM p.D84N Stable disease, alive at age 39
QRS time, Normal Wildtype Healthy at age 61
76 ms, nor- DCM p.D84N NYHA class II, alive at age 58
al DCM p.D84N NSVT once, alive at age 42
lete LBBB,
ies
Normal p.D84N MI at age 66, alive at age 78
Uncertain – Death at age of 4 months of heart muscle
disease
Uncertain – Death at age of 3 days of heart muscle
disease
DCM – SD at age 41. Dilated, hypertrophied
heart and lung emboli at autopsy
al Normal p.D84N Asymptomatic at age 42
DCM p.D84N ICD implanted, alive at age 77
and ventric- DCM p.D84N ICD implanted after cardiac arrest,
assessed for transplant, SD at age 68
Uncertain – Death from heart problem at age 6
Uncertain – Heart problems, death at age 75
arization Normal Wildtype Asymptomatic at age 12
Uncertain – Asymptomatic
Uncertain – Asymptomatic
Uncertain – Asymptomatic
pathy, NYHA = functional class according to the New York Heart Association, NSVT =
ioverter deﬁbrillator.
Fig. 2. A. Electropherograms depicting the nucleotide changes and consequent amino acid changes of the TPM1 p.D84N mutation in the proband. B. Alignment of part of the TPM1
protein of various species, indicating that the D84N mutation occurs in an evolutionarily highly conserved area. C. Representative gel of a GST-TPM1/actin co-sedimentation assay.
The left panel shows the supernatant (S) and pellet (P) phases of wildtype TPM1/actin, the middle panel D84N TPM1/actin, and the right panel the positive control of porcine mus-
cle TPM1/actin (without GST tag, notice the lower molecular weight). A representative gel of a HIS-TPM1/actin co-sedimentation assay is also shown indicating that the mutation
has a less intense binding of actin. Bar diagrams represent the averaged measured intensity of the TPM1 wildtype band (#) in comparison with that of TPM1 D84N band ($) after
co-sedimentation in the pellet phase, n=5, SD.
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co-sedimentation with tropomyosin from porcine muscle and actin
(Fig. 2C right panel), showing efﬁcient, and reproducible binding of
tropomyosin to actin with almost no tropomyosin in supernatant
phase. Subsequently, the co-sedimentation assay was performed using
the human GST-TPM1 wildtype and mutant protein. The intensity of
the staining was measured for the GST-TPM1 band in the pellet
(Fig. 2C, symbol #) for bothwildtype andD84N TPM1. The actin staining
was used as an internal loading control. Although this reaction was less
efﬁcient, as the majority of GST-tropomyosin remained in the superna-
tant, the binding capacity of mutant D84N TPM1 for actinwasmodestly,
but signiﬁcantly reduced by ±25% (pb0.001, n=5, Fig. 2C) in compar-
isonwith that ofwildtype TPM1. To rule out that the large GST-tag inter-
fered with the assay, we repeated the assay using HIS-tagged wildtype
and mutant TPM1. We found a similar reduction in binding of actin by
mutant TPM1 (Fig. 2C). Taken together, these results indicate that the
tropomyosin mutation adversely affects actin binding.
3.4. Putative effect of tropomyosin Asp84 to charge–charge interactions
with actin
Fig. 3A shows a ribbon representation of a segment of tropomyo-
sin based on the X-ray crystal structure of tropomyosin [25]. Knownmutated residues, Glu40, Glu54, Arg91(Beta-tropomyosin [26]) and
the Asp84 described here, are shown in bold. In Fig. 3B (stereoscopic
view) and 3C (close-up) we show an atomic model of the binding of
TPM1 to actin constructed by Pirani and co-workers [21]. Blue colors
denote positively charged areas and residues, while red colors denote
negatively charged ones. Although exact atomic distances may be
under- or overestimated, it is clear that the negatively charged
wildtype Asp84 (red) is in close proximity to a positively charged
area (blue) on the actin molecule. As such, it is positioned in a way
that allows charge–charge interactions with actin. The introduction
of the mutant polar asparagine in this position would disturb such in-
teractions, especially in the Ca2+-state and would result in the weak-
ened binding of tropomyosin to actin as experimentally observed.
4. Discussion
There is considerable heterogeneity in the clinical features and age
at disease onset of DCM resulting from a single genemutation.Most ge-
netic DCM cases become apparent during the fourth or ﬁfth decade of
life, but ﬁrst signs can also be noticed in young children and the severity
of symptoms and survival, even in affectedmembers of the same family,
can vary considerably [27]. We have identiﬁed a novel missense muta-
tion (p.D84N) in alpha-tropomyosin in a large four-generation family
Fig. 3. A. Ribbon representation of a segment of tropomyosin based on the X-ray crystal structure of tropomyosin highlighting positions of key residues involved in TPM-actin in-
teractions. B. Stereoscopic view of an atomic model of the binding of TPM1 to actin [21], blue denotes areas of positively charged residues and red negatively charged residues. TPM1
appears as a ribbon. C. Same model as used in B, but viewed from above, showing the local charges on the actin surface in relation to those on TPM1, in particular in the area of the
mutation. Note that TPM1 positively charged (red) residues (Asp84) are in close contact with negatively charged (blue) areas on actin and vice versa (Arg91).
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the disease causingmutation. This is supported by several observations,
ﬁrstly, linkage and haplotype analysis show that a DCMdisease locus on
chromosome 15 (containing TPM1) co-segregates with the disease.
Secondly,we identiﬁed amutation in TPM1 that is present in all clinical-
ly affected family members, and no other mutations in DCM or HCM
genes were found. Thirdly, themutated p.D84N residue has been highly
conserved in vertebrates throughout evolution. Fourthly, the mutation
is predicted to weaken the binding of tropomyosin to actin in the
Ca2+ state and lastly the mutation signiﬁcantly weakens TPM1 binding
to actin.
The phenotype of the p.D84N mutation carriers ranges from dilated
cardiomyopathy with signs of non-compaction, resulting in (sudden)
death at the age of ﬁve, to asymptomatic at the age of 42 (or possibly
even older considering I-2). Several family members have been diag-
nosed with DCM at an age over 50, while three young children died of
suspected heart problems without a clear diagnosis. Only two TPM1
mutations associatedwithDCMhave been describedbefore in small nu-
clear families (E54K and E40K), both of which are associated with se-
vere, early onset DCM, arrhythmias and cardiac heart transplantation,
but also with asymptomatic carriers [12], being in line with the pheno-
type of the current family. This suggests that TPM1 DCMmutations not
only cause a highly diverse phenotype, but importantly, can include
death at young ages and severe, early onset cardiomyopathic forms. In
fact, the proband, who died at the age of ﬁve, also had signs of NCCM
and while this can be detected in patients with an initial diagnosis of
DCM or HCM [28], recent reports describe the co-occurrence of both
NCCM and DCM co-occurring in one family, analogous to the family
presented in this study [28–30]. The additional screening of 23 known
DCM/HCM genes by next generation sequencing did rule out a second
mutation in those genes, however we cannot rule out the possibility
that the diverse phenotype in this family might be caused by additional
mutations, or could be the effect of the genetic background. However,
why DCM TPM1 mutations can cause such diverse and severe forms
of cardiomyopathy remains to be solved. One possibility is that alter-
ations in protein stoichiometry, caused by a point mutation, may pro-
duce a poison polypeptide that disrupts myoﬁbrillar organization on
incorporation into the sarcomere and thereby result in the severephenotype. The fact that mutation carriers can be asymptomatic can
be explained by a regulatory mechanism that maintains the level of
myoﬁbrillar tropomyosin. Such amechanismswas shown in TPM1 het-
erozygote knockout mice, who have an approximately 50% reduction in
alpha-tropomyosin mRNA levels, but have no reduction in alpha-
tropomyosin protein [31]. Regardless of the underlying mechanism,
our data suggests that screening of TPM1 in families with both DCM
and NCCM is warranted.
TPM1mutationswere initially associatedwith HCM, also presenting
with diverse phenotypes, from a benign course to severe hypertrophy
with progression to DCMand heart failure [32–34]. In Japanese families,
missense mutations in the TPM1 gene have been associated with the
progression of HCM to DCM [32]. However, based on all available clini-
cal and in vitro data, our patients did not have such a HCM to DCM tran-
sition, as it would be extremely unlikely for end-stage HCM to present
as DCM or NCCM at the age of 2 years or as minimally symptomatic
and stable DCM diagnosed at 29 years of age. Furthermore, only one
of themutation carriers (III-5) showed hypertrophy of the heartmuscle
at autopsy, though in combinationwith a dilated heart.Moreover, the in
vitro characteristics of the mutant protein point to a loss of binding,
which is consistent with DCM.
Our in vitro results suggest thatmutant TPM1 binding to actin is sig-
niﬁcantly diminished, possibly caused by a weakened charge–charge
interaction of the protein, see below. Although the wildtype tropomyo-
sin from porcine muscle showed a more efﬁcient binding to actin com-
pared to the human one, we attribute that to the presence of the GST or
HIS tag, necessary for the production and isolation of human wildtype
andmutant protein. Asmentioned earlier, only twoDCM causingmuta-
tions are described for TPM1 so far, E54K and E40K [35]. Both these
DCMmutations are associated with a decreased Ca2+ sensitivity possi-
bly as a direct consequence of a weakened calcium-on interaction with
actin. In addition, a crystallographic study of tropomyosin at 7 Å re-
vealed that both E40 and E54 may contribute to the stability of the
TPM1 ﬁlaments via interchain salt bridging to R35 and K49 respectively
(Fig. 3A) [25]. The E40K and E54K mutations will disturb such interac-
tions, altering local tropomyosin structure and possibly the stability of
the intertwined TPM1 helices. However, even though the D84Nmutant
described here occurs at a similar position along the helical axis, it does
839J.B.A. van de Meerakker et al. / Biochimica et Biophysica Acta 1833 (2013) 833–839not appear to form interchain salt bridges like E40 and E54. Actually,
close inspection of actin–tropomyosin ﬁlament models in both the
Ca2+ and low-Ca2+ state, indicates that D84 may contribute to the
charge–charge interactions thought to be important for tropomyosin–
actin association [21]. Negatively charged residues, such as D84 are po-
sitioned in close proximity to positively charged residues on the actin
surface (and vice versa) and this may contribute to charge–charge in-
teractions. In fact, the positively charged residue R91 is found mutated
in the highly related beta-tropomyosin (TPM2) in cases of distal
arthrogryposes [26]. This R91 residue is well conserved and positioned
within the charge–charge range of negatively charged areas on actin in
the Ca2+ state. It therefore appears that reciprocally charged residues
on both actin and tropomyosin play a role in the interactions between
tropomyosin and actin in the Ca2+ state, and that disturbances herein
may underlie a hypotonic response and the observed hypocontractile
DCM phenotype. In the low Ca2+ state, the R-groups of these residues
become removed from the actin charge surface by distances in excess
of 20 Å, thereby probably weakening the charge-charge interaction.
Unfortunately, the generated atomic model does not include E40 or
E54, so no comparison can be made for these mutations regarding
charge–charge interactions. Taken together, it is not entirely clear
how TPM1 mutations cause DCM, but altered Ca2+ sensitivity, de-
creased tropomyosin–actin association and changed stability of the
intertwined TPM1 helices, are all likely to contribute to the ﬁnal
phenotype.
In conclusion, we present a large four-generation family with
DCM, NCCM and death at young age. A co-segregating TPM1 muta-
tion, p.D84N, was found in all clinically affected family members,
and results in a diminished binding of tropomyosin to actin, possibly
as a result of weakened charge–charge interactions. This suggests that
screening of TPM1 in patients and families with DCM and/or severe,
early onset forms of DCM or NCCM is warranted.
Acknowledgements
WethankK. Smeele, S. de Jong,M.Otten andM.A.Haagmans for excel-
lent technical support and the family members for their kind participa-
tion. This work was supported by grants from the Netherlands Heart
Foundation (96.006 to A.F.M.), and the European Community's Sixth
Framework Programme contract (‘HeartRepair’) LSHM-CT-2005-018630
(A.F.M).
References
[1] B.J. Maron, J.A. Towbin, G. Thiene, C. Antzelevitch, D. Corrado, D. Arnett, A.J. Moss,
C.E. Seidman, J.B. Young, Contemporary deﬁnitions and classiﬁcation of the car-
diomyopathies: an American Heart Association Scientiﬁc Statement from the
Council on Clinical Cardiology, Heart Failure and Transplantation Committee;
Quality of Care and Outcomes Research and Functional Genomics and Transla-
tional Biology Interdisciplinary Working Groups; and Council on Epidemiology
and Prevention, Circulation 113 (2006) 1807–1816.
[2] H.A. Valantine, S.A. Hunt, M.B. Fowler, M.E. Billingham, J.S. Schroeder, Frequency
of familial nature of dilated cardiomyopathy and usefulness of cardiac transplan-
tation in this subset, Am. J. Cardiol. 63 (1989) 959–963.
[3] S. Karkkainen, K. Peuhkurinen, Genetics of dilated cardiomyopathy, Ann. Med. 39
(2007) 91–107.
[4] V.V. Michels, P.P. Moll, F.A. Miller, A.J. Tajik, J.S. Chu, D.J. Driscoll, J.C. Burnett, R.J.
Rodeheffer, J.H. Chesebro, H.D. Tazelaar, The frequency of familial dilated cardio-
myopathy in a series of patients with idiopathic dilated cardiomyopathy, N. Engl.
J. Med. 326 (1992) 77–82.
[5] E. Grunig, J.A. Tasman, H. Kucherer, W. Franz, W. Kubler, H.A. Katus, Frequency
and phenotypes of familial dilated cardiomyopathy, J. Am. Coll. Cardiol. 31
(1998) 186–194.
[6] P.J. Keeling, Y. Gang, G. Smith, H. Seo, S.E. Bent, V. Murday, A.L. Caforio, W.J.
McKenna, Familial dilated cardiomyopathy in the United Kingdom, Br. Heart J.
73 (1995) 417–421.
[7] M.R. Taylor, E. Carniel, L. Mestroni, Cardiomyopathy, familial dilated, Orphanet J.
Rare Dis. 1 (2006) 27.
[8] M. Kamisago, S.D. Sharma, S.R. DePalma, S. Solomon, P. Sharma, B. McDonough, L.
Smoot, M.P. Mullen, P.K. Woolf, E.D. Wigle, J.G. Seidman, C.E. Seidman, Mutations
in sarcomere protein genes as a cause of dilated cardiomyopathy, N. Engl. J. Med.
343 (2000) 1688–1696.[9] D.S. Herman, L. Lam, M.R. Taylor, L. Wang, P. Teekakirikul, D. Christodoulou, L.
Conner, S.R. DePalma, B. McDonough, E. Sparks, D.L. Teodorescu, A.L. Cirino, N.R.
Banner, D.J. Pennell, S. Graw, M. Merlo, A. Di Lenarda, G. Sinagra, J.M. Bos, M.J.
Ackerman, R.N. Mitchell, C.E. Murry, N.K. Lakdawala, C.Y. Ho, P.J. Barton, S.A.
Cook, L. Mestroni, J.G. Seidman, C.E. Seidman, Truncations of titin causing dilated
cardiomyopathy, N. Engl. J. Med. 366 (2012) 619–628.
[10] J.P. Lees-Miller, D.M. Helfman, The molecular basis for tropomyosin isoform di-
versity, Bioessays 13 (1991) 429–437.
[11] S. Schiafﬁno, C. Reggiani, Molecular diversity of myoﬁbrillar proteins: gene regu-
lation and functional signiﬁcance, Physiol. Rev. 76 (1996) 371–423.
[12] T.M. Olson, N.Y. Kishimoto, F.G. Whitby, V.V. Michels, Mutations that alter the
surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy,
J. Mol. Cell. Cardiol. 33 (2001) 723–732.
[13] C. Seidman, Disease-causing mutations in the human alpha-tropomyosin gene, http://
genepath.med.harvard.edu/seidman//cg3/muts/TPM1_mutations_TOC.html 2012.
[14] P. Elliott, Cardiomyopathy. Diagnosis and management of dilated cardiomyopa-
thy, Heart 84 (2000) 106–112.
[15] J.L. Davies, Y. Kawaguchi, S.T. Bennett, J.B. Copeman, H.J. Cordell, L.E. Pritchard,
P.W. Reed, S.C. Gough, S.C. Jenkins, S.M. Palmer, et al., A genome-wide search
for human type 1 diabetes susceptibility genes, Nature 371 (1994) 130–136.
[16] T.H. Lindner, K. Hoffmann, easyLINKAGE: a PERL script for easy and automated
two-/multi-point linkage analyses, Bioinformatics 21 (2005) 405–407.
[17] G.R. Abecasis, S.S. Cherny, W.O. Cookson, L.R. Cardon, Merlin—rapid analysis of
dense genetic maps using sparse gene ﬂow trees, Nat. Genet. 30 (2002) 97–101.
[18] P.A. Underhill, L. Jin, A.A. Lin, S.Q. Mehdi, T. Jenkins, D. Vollrath, R.W. Davis, L.L.
Cavalli-Sforza, P.J. Oefner, Detection of numerous Y chromosome biallelic poly-
morphisms by denaturing high-performance liquid chromatography, Genome
Res. 7 (1997) 996–1005.
[19] P. Barnett, G. Bottger, A.T. Klein, H.F. Tabak, B. Distel, The peroxisomal membrane
protein Pex13p shows a novel mode of SH3 interaction, EMBO J. 19 (2000)
6382–6391.
[20] J.M. Ruijter, H.H. Thygesen, O.J. Schoneveld, A.T. Das, B. Berkhout, W.H. Lamers,
Factor correction as a tool to eliminate between-session variation in replicate ex-
periments: application to molecular biology and retrovirology, Retrovirology 3
(2006) 2.
[21] A. Pirani, M.V. Vinogradova, P.M. Curmi, W.A. King, R.J. Fletterick, R. Craig, L.S.
Tobacman, C. Xu, V. Hatch, W. Lehman, An atomic model of the thin ﬁlament in
the relaxed and Ca2+-activated states, J. Mol. Biol. 357 (2006) 707–717.
[22] D. Fatkin, C. MacRae, T. Sasaki, M.R. Wolff, M. Porcu, M. Frenneaux, J. Atherton, H.J.
Vidaillet Jr., S. Spudich, U. De Girolami, J.G. Seidman, C. Seidman, F. Muntoni, G.
Muehle, W. Johnson, B. McDonough, Missense mutations in the rod domain of
the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system
disease, N. Engl. J. Med. 341 (1999) 1715–1724.
[23] T.M. Olson, V.V. Michels, S.N. Thibodeau, Y.S. Tai, M.T. Keating, Actin mutations in
dilated cardiomyopathy, a heritable form of heart failure, Science 280 (1998)
750–752.
[24] NHLBI, Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle,
WA, 2012. (http://evs.gs.washington.edu/EVS/).
[25] F.G. Whitby, G.N. Phillips Jr., Crystal structure of tropomyosin at 7 angstroms res-
olution, Proteins 38 (2000) 49–59.
[26] P. Robinson, S. Lipscomb, L.C. Preston, E. Altin, H.Watkins, C.C. Ashley, C.S. Redwood,
Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause
distal arthrogryposis all increase contractile function, FASEB J. 21 (2007) 896–905.
[27] J. Schonberger, C.E. Seidman, Many roads lead to a broken heart: the genetics of
dilated cardiomyopathy, Am. J. Hum. Genet. 69 (2001) 249–260.
[28] R.T. Murphy, R. Thaman, J.G. Blanes, D. Ward, E. Sevdalis, E. Papra, A.
Kiotsekoglou, M.T. Tome, D. Pellerin, W.J. McKenna, P.M. Elliott, Natural history
and familial characteristics of isolated left ventricular non-compaction, Eur.
Heart J. 26 (2005) 187–192.
[29] R.H. Pignatelli, C.J. McMahon, W.J. Dreyer, S.W. Denﬁeld, J. Price, J.W. Belmont,
W.J. Craigen, J. Wu, H. El Said, L.I. Bezold, S. Clunie, S. Fernbach, N.E. Bowles, J.A.
Towbin, Clinical characterization of left ventricular noncompaction in children:
a relatively common form of cardiomyopathy, Circulation 108 (2003) 2672–2678.
[30] Y.M. Hoedemaekers, K. Caliskan, D. Majoor-Krakauer, I. van de Laar, M. Michels,
M. Witsenburg, F.J. ten Cate, M.L. Simoons, D. Dooijes, Cardiac beta-myosin
heavy chain defects in two families with non-compaction cardiomyopathy:
linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopa-
thies, Eur. Heart J. 28 (2007) 2732–2737.
[31] E.M. Blanchard, K. Iizuka, M. Christe, D.A. Conner, A. Geisterfer-Lowrance, F.J.
Schoen, D.W. Maughan, C.E. Seidman, J.G. Seidman, Targeted ablation of the mu-
rine alpha-tropomyosin gene, Circ. Res. 81 (1997) 1005–1010.
[32] K. Yamauchi-Takihara, C. Nakajima-Taniguchi, H. Matsui, Y. Fujio, K. Kunisada, S.
Nagata, T. Kishimoto, Clinical implications of hypertrophic cardiomyopathy asso-
ciated with mutations in the alpha-tropomyosin gene, Heart 76 (1996) 63–65.
[33] D.A. Coviello, B.J. Maron, P. Spirito, H. Watkins, H.P. Vosberg, L. Thierfelder, F.J.
Schoen, J.G. Seidman, C.E. Seidman, Clinical features of hypertrophic cardiomyop-
athy caused by mutation of a “hot spot” in the alpha-tropomyosin gene, J. Am.
Coll. Cardiol. 29 (1997) 635–640.
[34] V. Regitz-Zagrosek, J. Erdmann, E. Wellnhofer, J. Raible, E. Fleck, Novel mutation in
the alpha-tropomyosin gene and transition fromhypertrophic to hypocontractile di-
lated cardiomyopathy, Circulation 102 (2000) E112–E116.
[35] M. Mirza, P. Robinson, E. Kremneva, O. Copeland, O. Nikolaeva, H. Watkins, D.
Levitsky, C. Redwood, M. El-Mezgueldi, S. Marston, The effect of mutations in
alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy
on the regulatory mechanism of cardiac muscle thin ﬁlaments, J. Biol. Chem. 282
(2007) 13487–13497.
